# A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

> **NCT03978520** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 341 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Elsubrutinib
- **DRUG:** Placebo for elsubrutinib
- **DRUG:** Upadacitinib
- **DRUG:** Placebo for upadacitinib

## Key facts

- **NCT ID:** NCT03978520
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-25
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-07-14
- **Target enrollment:** 341 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978520, "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03978520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*